GLPG1690
≥98%
- Product Code: 53052
CAS:
1628260-79-6
| Molecular Weight: | 588.70 g./mol | Molecular Formula: | C₃₀H₃₃FN₈O₂S |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD31544330 | |
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | 2-8°C, dry and sealed |
Product Description:
GLPG1690 is primarily investigated for its potential therapeutic applications in treating idiopathic pulmonary fibrosis (IPF), a chronic and progressive lung disease. It functions as an autotaxin inhibitor, targeting the enzyme autotaxin, which plays a role in the production of lysophosphatidic acid (LPA). Elevated levels of LPA are associated with fibrosis, inflammation, and tissue remodeling in IPF. By inhibiting autotaxin, GLPG1690 aims to reduce LPA levels, thereby slowing disease progression and improving lung function. Clinical trials have explored its efficacy and safety, showing promise in reducing fibrosis and improving patient outcomes. Additionally, research is ongoing to evaluate its potential in other fibrotic or inflammatory conditions beyond IPF.
Product Specification:
| Test | Specification |
|---|---|
| APPEARANCE | White solid powder |
| PURITY | 97.5-100 |
| Infrared spectrum | Conforms to Structure |
| NMR | Conforms to Structure |
Sizes / Availability / Pricing:
| Size (g) | Availability | Price | Quantity |
|---|---|---|---|
| 0.005 | 10-20 days | ฿1,500.00 |
+
-
|
| 0.010 | 10-20 days | ฿2,500.00 |
+
-
|
| 0.050 | 10-20 days | ฿7,450.00 |
+
-
|
| 0.250 | 10-20 days | ฿20,180.00 |
+
-
|
GLPG1690
GLPG1690 is primarily investigated for its potential therapeutic applications in treating idiopathic pulmonary fibrosis (IPF), a chronic and progressive lung disease. It functions as an autotaxin inhibitor, targeting the enzyme autotaxin, which plays a role in the production of lysophosphatidic acid (LPA). Elevated levels of LPA are associated with fibrosis, inflammation, and tissue remodeling in IPF. By inhibiting autotaxin, GLPG1690 aims to reduce LPA levels, thereby slowing disease progression and improving lung function. Clinical trials have explored its efficacy and safety, showing promise in reducing fibrosis and improving patient outcomes. Additionally, research is ongoing to evaluate its potential in other fibrotic or inflammatory conditions beyond IPF.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Cart
No products
Subtotal:
฿0.00
฿0.00
Total :